When your patient is discharged from cellular immunotherapy treatment at Fred Hutch Cancer Center, we will send you a discharge packet, including information about our Cellular Immunotherapy Long-Term Follow-Up (LTFU) Program. The guidelines below may also be helpful.
Please Read Below Before Accessing the Physician Guidelines
These guidelines and the information they contain are copyrighted material of Fred Hutchinson Cancer Center, all rights reserved. They are intended solely for the use of referring physicians who are involved in the care of patients who have had cellular immunotherapy at Fred Hutch. They may not be used for any other purpose, and Fred Hutch disclaims all liability for the use of these guidelines except as expressly permitted by Fred Hutch. No portion of these guidelines may be copied, displayed for redistribution to third parties for commercial purposes or for any non-permitted use without the prior written permission of Fred Hutch.
These guidelines have been developed based on the available literature and the experience of physicians and patients at Fred Hutch. These guidelines are periodically updated and therefore should be re-confirmed before use. Recommendations in these guidelines must be implemented in a medically reasonable way that is based upon the independent medical judgment of the treating physician and which accounts for the specific situation of the individual patient. Recommendations for patients who are enrolled in specific protocols may differ from the recommendations in these guidelines and will be communicated separately. Questions concerning the recommendations in these guidelines or their application to particular patients should be directed to the Cellular Immunotherapy LTFU office (phone: 206.667.5811 or email: imtxltfu@fredhutch.org).
Guidelines and Information
Immunotherapy (IMTX): Vaccination After B Cell-Targeted CAR T-Cell Therapy for Adult and Pediatric Immunotherapy Patients
Summary: Vaccination Guidelines After B-Cell and Plasma Cell Targeted CAR T Cell (Providers)
Published Papers
These are selected publications by Fred Hutch researchers related to care for patients after cellular immunotherapy.
Late Effects after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen receptor T Cell Therapy
Contact Cellular Immunotherapy LTFU
Hours: Monday–Friday, 8 a.m.–4 p.m.
Mailing Address:
Fred Hutch Cancer Center
ATTN: IMTX LTFU
1100 Fairview Ave. N
Mail Stop M2-A876
Seattle, WA 98109